Icahn School of Medicine at Mount Sinai

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).

708 total trials 163 currently recruiting 423 completed early-phase tilt top decile by trial count

Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.

Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.

Top-decile sponsor footprint

Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

708 total, page 4 of 15

RECRUITING Phase 4

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

NCT03781765

RECRUITING NA

The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU

NCT03642002

RECRUITING

Evaluation of an EEG Based Concussion System

NCT03710109

RECRUITING

Upright MRI for Prostate Cancer Screening

NCT03474913

RECRUITING

DDX3X Syndrome -The Seaver Autism Center for Research and Treatment is Characterizing DDX3X-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718910

RECRUITING Phase 4

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

NCT03781752

RECRUITING

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718936

RECRUITING NA

Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome

NCT03533985

RECRUITING

FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.

NCT03718923

RECRUITING

Defining the Basis of Fibromuscular Dysplasia (FMD)

NCT01967511

RECRUITING

Pancreas Registry and High Risk Registry

NCT02775461

RECRUITING

WTC Chest CT Imaging Archive

NCT03295279

RECRUITING

Longitudinal Study of the Porphyrias

NCT01561157

ACTIVE NOT RECRUITING

Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer

NCT06412874

ACTIVE NOT RECRUITING Phase 4

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

NCT06618976

ACTIVE NOT RECRUITING Phase 2

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

NCT06069843

ACTIVE NOT RECRUITING NA

Non-Invasive Median Nerve Stimulation to Attenuate Atrial Tachyarrhythmias After Catheter Ablation for Atrial Fibrillation

NCT06748157

ACTIVE NOT RECRUITING NA

Multi-sensory Intervention Room Application (MIRA) Device in the NSICU

NCT06509815

ACTIVE NOT RECRUITING

A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)

NCT03963817

ACTIVE NOT RECRUITING Early Phase 1

Targeting Drug Memories With Methylphenidate

NCT05978167

ACTIVE NOT RECRUITING NA

Palliative Care for Patients With Dementia

NCT05749146

ACTIVE NOT RECRUITING NA

Kaneka iED Coil System for the Treatment of Wide Necked Ruptured and Unruptured Intracranial Aneurysms

NCT05636124

ACTIVE NOT RECRUITING Phase 1

Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease

NCT03992469

ACTIVE NOT RECRUITING Early Phase 1

A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT05560399

ACTIVE NOT RECRUITING Phase 1

Long Acting Neuraxial Peri-prostatic Block in Cancer

NCT06703437

ACTIVE NOT RECRUITING

Improving Outcomes for Older Adults Undergoing Radiation Therapy

NCT05721053

ACTIVE NOT RECRUITING Phase 1

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

NCT05119140

ACTIVE NOT RECRUITING NA

NRF for Improved Re-Entry Outcomes for Offenders With Brain Injury (Brain Injury RE)

NCT05708092

ACTIVE NOT RECRUITING Early Phase 1

ESP/PIF for Sternotomy

NCT04985500

ACTIVE NOT RECRUITING

Impact of COVID-19 on GU Disease

NCT04761107

ACTIVE NOT RECRUITING NA

Mindfulness-Oriented Recovery Enhancement (MORE) in Heroin Addiction

NCT04112186

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

NCT04123379

ACTIVE NOT RECRUITING

Real World and Genomic Data Based Asthma Insight Through Network Analysis

NCT06623435

ACTIVE NOT RECRUITING NA

Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease

NCT03850600

ACTIVE NOT RECRUITING Phase 1

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

NCT03304080

ACTIVE NOT RECRUITING NA

Multicenter Phase II Study of Transanal TME (taTME)

NCT03144765

ACTIVE NOT RECRUITING

Long Term Follow Up for CTSN Mitral Valve Repair Studies

NCT03066050

ACTIVE NOT RECRUITING NA

Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

NCT02945631

ACTIVE NOT RECRUITING

Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones

NCT03025763

ACTIVE NOT RECRUITING Phase 3

The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

NCT01706939

NOT YET RECRUITING

Gestational Changes in Hemodynamics and Respiratory Mechanics in Association With Pre-Eclampsia

NCT07695909

NOT YET RECRUITING

Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)

NCT07671599

NOT YET RECRUITING NA

The LIFT-ECHO Last Mile Project

NCT07094308

NOT YET RECRUITING

Chronic Subdural Hematoma Embolization With Detachable Coils

NCT07291427

NOT YET RECRUITING

Quantifying the Burden of Type 2 (T2) Inflammation in Asthma

NCT07675044

NOT YET RECRUITING Phase 2

Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity

NCT07572175

NOT YET RECRUITING NA

High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction

NCT07194187

NOT YET RECRUITING Phase 2

SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction

NCT07597902

NOT YET RECRUITING

Delayed Toxicities Post-CAR-T

NCT07665307

NOT YET RECRUITING Phase 4

Remimazolam Versus Dexmedetomidine for Sedation During Neuraxial

NCT07651956

← Previous Page 4 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 81
Phase 3 21
Phase 4 67

What is open in the Icahn School of Medicine at Mount Sinai pipeline

163 recruiting of 708 indexed (23% open); 423 completed (60%).

Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide

Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Icahn School of Medicine at Mount SinaiSanofiWeill Medical College of Cornell UniversityUniversity of MiamiThe Cleveland ClinicClemson UniversityLiberating TechnologiesRahul AggarwalSequenom
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 708 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

What to do with this Icahn School of Medicine at Mount Sinai page

708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.

  • 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.